Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Vanguard High Dividend Yield ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $508.92 (market cap $127.55B), while Vanguard High Dividend Yield ETF trades at $158.59 (market cap $100.80B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Vanguard High Dividend Yield ETF is more actively traded (908,176 versus 1,487,944). Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Vanguard High Dividend Yield ETF for 138 Days on average.
| VRTX | VYM | |
|---|---|---|
Market Cap | $127.55B | $100.80B |
Volume | 1,487,944 | 908,176 |
Sector | Health | — |
52-Week High | $557.96 | $167.03 |
52-Week Low | $407.37 | $137.47 |
Typical Hold Time | 120 Days | 138 Days |
Enterprise Value | $121.68B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
VYM trades at $157.45, down 0.58% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with support at $157 and resistance at $158. Recent news highlights VYM's consistent dividend yield of 2.42% but notes performance lag versus peers like SCHD and IDV, which have outperformed year-to-date.
VYM faces competition from higher-yielding alternatives and exhibits vulnerability to dividend cuts in its holdings. The ETF's broad diversification provides stability, but investors may seek better returns elsewhere. Key risks include sector concentration and interest rate sensitivity affecting dividend appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
